Maqola

Cefiderocol (CFDC): A Spy Antibiotic Future Replacement of Carbapenem

Md. Rezwan Ahmed MahediDepartment of Pharmacy, Comilla University, BangladeshKamilia MounichUniversity Hassan 2, sciences faculty ain chock, LIPE, MoroccoChou‐Yi HsuDepartment of Pharmacy, Chia Nan University of Pharmacy and Science, TaiwanJamilur Rahman BhuiyanDepartment of Pharmacy, Jahangirnagar University, BangladeshIhsan K. JasimDepartment of Pharmacology, Al-Turath University College, Baghdad, IraqOthman Othman Mahjoob KhalafCollege of Education, Al-Farahidi University, Baghdad, IraqDarshan JCAssistant Professor, Department of Pharmacy Practice, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to be University), Ayush Campus, Naringana, Mangaluru, Karnataka, India, 575018Calvin R. WeiMehrab Binte MushfiqueHoly Family Red Crescent Medical College, Dhaka, BangladeshΝikolaos SyrmosAristotle University of Thessaloniki, Thesaaloniki, Macedonia, GreeceSadia AfrinDepartment of Pharmacy, Comilla University, BangladeshPeter SinghSchool of pharmacy, Brac University

2023en

ABI

Annotatsiya

Cefiderocol, also known as CFDC, is an antibiotic in the class of cephalosporins. It is from the third generation. It is effective against gram-negative bacteria. 2019 was the year that it was given US FDA approval for use in the treatment of UTIs. In recent years, there has been a dramatic rise in the prevalence of MDR due to the increased use of antibiotics. Carbapenem, which is a broad-spectrum antibiotic, is unable to treat the illness for this reason because bacteria have developed resistance to it. In this scenario, cefiderocol may be used for the therapy of this kind of infection, and it would also be of special assistance for the treatment of GNB in individuals who have few other therapeutic options available to them. For this review, studies published between 2007 and 2023 are the primary focus of the debate. This review's supporting materials were sourced via a combined search of PubMed, PubChem, and Google Scholar, including the terms "Cefiderocol," "Carbapenem," "Gram-negative Bacteria," "Carbapenem Resistance," and "Cefiderocol clinical trials" from 2007 until May 2023. The focus of this paper is the difference in mode of action of these two antibiotics and shows valid issues for carbapenem resistance.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.52711/0974-360x.2023.00888

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar